P. Smith

发表

Oral anticoagulants are effective long term after acute myocardial infarction

P. Smith, 1999, Journal of internal medicine.

Factor analysis of plasma lipoprotein components.

I. Aursnes, K. Berg, E. Christiansen, 1988, Atherosclerosis.

Analysis of the postulated interaction between the angiotensin II sub-type 1 receptor gene A1166C polymorphism and the insertion/deletion polymorphism of the angiotensin converting enzyme gene on risk of myocardial infarction.

N. Samani, R. Steeds, K. Channer, 2001, Atherosclerosis.

Distribution of Tissue Plasminogen Activator Insertion/Deletion Polymorphism in Myocardial Infarction and Control Subjects

N. Samani, R. Steeds, K. Channer, 1998, Thrombosis and Haemostasis.

Effects of Gemfibrozil on Lipids and Haemostasis after Myocardial Infarction

H. Arnesen, I. Seljeflot, Pål J. Smith, 1990, Thrombosis and Haemostasis.

One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial.

P. Hoff, V. Hansteen, A. Andersen, 1982, British medical journal.

Withdrawal of chronic beta- adrenoceptorblockade: Effects on haemodynamics, blood lipids and haemostatic variables

T. Opstad, I. Seljeflot, P. Smith, 2007, European Journal of Clinical Pharmacology.

Comparison of bleeding complications of warfarin and warfarin plus acetylsalicylic acid: a study in 3166 outpatients

H. Arnesen, J. Erikssen, Pål J. Smith, 1994, Journal of internal medicine.

Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction.

N. Samani, J. Thompson, D. Martin, 1996, QJM : monthly journal of the Association of Physicians.

Effects of long-term treatment with warfarin on fibrinogen, FPA, TAT, and D-dimer in patients with coronary artery disease.

H. Arnesen, I. Seljeflot, A. Westvik, 1992, Thrombosis research.

Influence of highly concentrated n-3 fatty acids on serum lipids and hemostatic variables in survivors of myocardial infarction receiving either oral anticoagulants or matching placebo.

H. Arnesen, T. Opstad, K. Dahl, 1989, Thrombosis research.

Warfarin and uric acid after myocardial infarction.

H. Arnesen, P. Smith, 2009, Acta medica Scandinavica.

Correlation between plasma levels of selenium and antithrombin‐III

H. Arnesen, I. Aursnes, B. Åkesson, 1988, European journal of haematology.

Differential regulation of ventricular adrenomedullin and atrial natriuretic peptide gene expression in pressure and volume overload in the rat.

N. Samani, C. Aalkjaer, M. Kaiser, 1998, Clinical science.

Functional measurement of t-PA in plasma using a bead immuno chromogenic assay (BICA)

G. Gogstad, K. Dahl, P. Smith, 1987 .

Long-term anticoagulant treatment after acute myocardial infarction. The Warfarin Re-Infarction Study.

P. Smith, 1992, Annals of epidemiology.

D-dimer Agglutination Test in the Evaluation of Fibrinolytic Capacity after Stimulation with DDAVP

H. Arnesen, I. Seljeflot, P. Smith, 1990 .

Warfarin has no negative impact on fibrinolysis.

H. Arnesen, T. Opstad, P. Kierulf, 1990, Thrombosis research.

D-dimer test after standardized coagulation: A new assay for global evaluation of the unstimulated fibrinolytic system

H. Arnesen, I. Seljeflot, J. Eritsland, 1993 .

Effects of long-term anticoagulant therapy in subgroups after acute myocardial infarction.

H. Arnesen, M. Abdelnoor, P. Smith, 1992, Archives of internal medicine.

The effect of warfarin on mortality and reinfarction after myocardial infarction.

P Smith, I. Holme, H. Arnesen, 1990, The New England journal of medicine.

The predictability of bleeding by prothrombin times sensitive or insensitive to PIVKA during intensive oral anticoagulation.

H. Arnesen, P. Smith, 1991, Thrombosis research.

FACTOR VII-PHOSPHOLIPID COMPLEX IN MALE SURVIVIRS OF ACUTE MYCORDIAL INFARCTION

P Smith, H. Prydz, H. Arnesen, 2009, Thrombosis and Haemostasis.

Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design.

H. Arnesen, Pål J. Smith, P. Smith, 2000, Scandinavian cardiovascular journal : SCJ.

Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke

H. Arnesen, M. Abdelnoor, F. Wisløff, 1992, The Lancet.

Changes in EPA and DHA during supplementation with omega-3 fatty acids and incident cardiovascular events: secondary analysis from the OMEMI trial

A. Tveit, H. Arnesen, S. Solheim, 2021, European Heart Journal.

Mortality in non‐consenters in a post‐myocardial infarction trial

H. Arnesen, P. Smith, 1990, Journal of internal medicine.

Non-respondents in a post-myocardial infarction trial: characteristics and reasons for refusal.

H. Arnesen, Pål J. Smith, P. Smith, 2009, Acta medica Scandinavica.

Myocardial infarction may induce positive changes in life-style and in the quality of life.

E. Laerum, S. Larsen, P. Smith, 1988, Scandinavian journal of primary health care.

Low and high risk coronary patients discriminated by blood platelet fatty acid composition.

H. Arnesen, S. Fischer, I. Aursnes, 1986, Scandinavian journal of clinical and laboratory investigation.

Positive psychological and life-style changes after myocardial infarction: a follow-up study after 2-4 years.

H. Arnesen, E. Laerum, P. Smith, 1991, Family practice.

Can myocardial infarction induce positive changes in family relationships?

E. Laerum, S. Larsen, P. Smith, 1987, Family practice.

Utility of a Modified Calibration Model for Reliable Conversion of Thromboplastin Times to International Normalized Ratios

G. Gogstad, P. Smith, J. Wadt, 1986, Thrombosis and Haemostasis.

A comparative study of venous occlusion and DDAVP stimulated fibrinolysis in normolipidemic subjects.

D. Nilsen, H. Arnesen, T. Opstad, 1988, Thrombosis research.

Changes in fibrinolytic capacity and lipoprotein pattern during long-term treatment with warfarin.

H. Arnesen, P. Smith, E. Aspelund, 1986, Thrombosis research.